Literature DB >> 2944381

Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis.

V Arroyo, P Ginés, A Rimola, J Gaya.   

Abstract

The ability of the kidneys to excrete sodium and free water is often impaired in patients with cirrhosis. Sodium retention is a sine qua non for ascites formation. The impairment of water excretion causes hyponatremia and hypo-osmolality. In addition, these patients frequently have functional renal failure caused by intense renal vasoconstriction. The renin-angiotensin-aldosterone system and the sympathetic nervous system, which are activated in most cirrhotic patients with ascites, and a nonosmotic hypersecretion of antidiuretic hormone are important mechanisms of sodium and water retention. Angiotensin II and sympathetic nervous activity may also be involved in the pathogenesis of functional renal failure. The renal production of prostaglandins is increased in cirrhotic patients with ascites as a homeostatic response to antagonize the vascular effect of endogenous vasoconstrictors and the tubular action of antidiuretic hormone. Nonsteroidal anti-inflammatory drugs should, therefore, be administered with caution in these patients because they may induce acute renal failure and water retention. Although sulindac inhibits the renal synthesis of prostaglandins in cirrhotic patients with ascites, it appears to have less effect on renal function than do other nonsteroidal anti-inflammatory drugs administered to these patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944381     DOI: 10.1016/0002-9343(86)90912-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  21 in total

Review 1.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

Review 2.  The endocrinology and pathophysiology of alcoholic cirrhosis and functional renal failure--a review.

Authors:  E S Domurat; A N Elias
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

3.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 4.  Hepatorenal syndrome.

Authors:  Sharon Turban; Paul J Thuluvath; Mohamed G Atta
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

5.  Medical Care of the Patient With Compensated Cirrhosis.

Authors:  Jorge L Herrera; Reynaldo Rodríguez
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-02

6.  Reversibility of hepatopulmonary syndrome evidenced by serial pulmonary perfusion scan.

Authors:  H Shijo; H Sasaki; H Sakata; H Kusuhara; T Ueki; M Okumura
Journal:  Gastroenterol Jpn       Date:  1993-02

Review 7.  Management of hepatorenal syndrome in patients with cirrhosis.

Authors:  Vicente Arroyo; Javier Fernández
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

8.  Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.

Authors:  Marta López-Parra; Joan Clària; Anna Planagumà; Esther Titos; Jaime L Masferrer; B Mark Woerner; Alane T Koki; Wladimiro Jiménez; Rosario Altuna; Vicente Arroyo; Francisca Rivera; Joan Rodés
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 9.  Pharmacotherapy of ascites associated with cirrhosis.

Authors:  P Ginès; V Arrovo; J Rodés
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

10.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.